Combined TLR7/8 and TLR9 Ligands Potentiate the Activity of a Schistosoma japonicum DNA Vaccine

PLoS Neglected Tropical Diseases

Volumn 7, Issue 4, 2013, Pages

  Wang, Xuefeng ^a,b   Dong, Liyang ^a   Ni, Hongchang ^a   Zhou, Sha ^c   Xu, Zhipeng ^c   Hoellwarth, Jason Shih ^d   Chen, Xiaojun ^c   Zhang, Rongbo ^b   Chen, Qiaoyun ^a   Liu, Feng ^c   Wang, Jun ^a   Su, Chuan ^c  

^a JIANGSU UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PVAX1 SCHISTOSOMA JAPONICUM 26 KDA GLUTATHIONE S TRANSFERASE DNA; RESIQUIMOD; SCHISTOSOMA VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; SPLEEN CELL; UPREGULATION;

EID: 84876875660     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002164     Document Type: Article

References (68)

1. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, et al. (2008) Helminth infections: the great neglected tropical diseases. J Clin Invest 118: 1311-1321.
2. King CH, (2009) Toward the elimination of schistosomiasis. N Engl J Med 360: 106-109.
3. Doenhoff MJ, Cioli D, Utzinger J, (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659-667.
4. Abdul-Ghani R, Loutfy N, El-Sahn A, Hassan A, (2009) Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges. Parasitol Res 104: 955-965.
5. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, et al. (2009) The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 136: 1719-1730.
6. McManus DP, Loukas A, (2008) Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21: 225-242.
7. Bergquist NR, Leonardo LR, Mitchell GF, (2005) Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 21: 112-117.
8. Aloysius MM, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, et al. (2009) Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med 7: 18.
9. Toka FN, Suvas S, Rouse BT, (2004) CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J Virol 78: 13082-13089.
10. Wang X, Zhou S, Chi Y, Wen X, Hoellwarth J, et al. (2009) CD4+CD25+ Treg induction by an HSP60-derived peptide SJMHE1 from Schistosoma japonicum is TLR2 dependent. Eur J Immunol 39: 3052-3065.
11. Tang CL, Lei JH, Wang T, Lu SJ, Guan F, et al. (2011) Effect of CD4+ CD25+ regulatory T cells on the immune evasion of Schistosoma japonicum. Parasitol Res 108: 477-480.
12. Nausch N, Midzi N, Mduluza T, Maizels RM, Mutapi F, (2011) Regulatory and activated T cells in human Schistosoma haematobium infections. PLoS One 6: e16860.
13. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, et al. (2007) Immunopathology of schistosomiasis. Immunol Cell Biol 85: 148-154.
14. Maizels RM, Smith KA, (2011) Regulatory T cells in infection. Adv Immunol 112: 73-136.
15. Cabrera G, Mundinano J, Camicia G, Costa H, Nepomnaschy I, et al. (2011) [Regulatory T cell depletion increases the number of CD8 cells during mouse mammary tumor virus infection]. Medicina (B Aires) 71: 243-246.
16. Dietze KK, Zelinskyy G, Gibbert K, Schimmer S, Francois S, et al. (2011) Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A 108: 2420-2425.
17. Akira S, Takeda K, Kaisho T, (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680.
18. Hedayat M, Netea MG, Rezaei N, (2011) Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 11: 702-712.
19. Chiffoleau E, Heslan JM, Heslan M, Louvet C, Condamine T, et al. (2007) TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol 19: 193-201.
20. LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA, et al. (2007) CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 108: 183-188.
21. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, et al. (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309: 1380-1384.
22. Salem ML, El-Demellawy M, El-Azm AR, (2010) The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 262: 96-104.
23. Panter G, Kuznik A, Jerala R, (2009) Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr Opin Mol Ther 11: 133-145.
24. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA, (2010) Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 14: e781-787.
25. Wang X, Liu F, Zhou S, Xu Z, Hoellwarth J, et al. (2012) Partial regulatory T cell depletion prior to schistosomiasis vaccination does not enhance the protection. PLoS One 7: e40359.
26. Steinhagen F, Kinjo T, Bode C, Klinman DM, (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
27. Wang X, Zhang L, Chi Y, Hoellwarth J, Zhou S, et al. (2010) The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy. Parasit Vectors 3: 109.
28. Wei F, Liu Q, Gao S, Shang L, Zhai Y, et al. (2008) Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26 kDa GST plasmid DNA vaccine in mice. Vaccine 26: 4145-4149.
29. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, et al. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265.
30. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD, (2011) Vaccine adjuvant activity of 3 M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29: 5434-5442.
31. Zhang L, Yang Y, Yang X, Zhao J, Yang J, et al. (2008) T cell epitope-based peptide-DNA dual vaccine induces protective immunity against Schistosoma japonicum infection in C57BL/6J mice. Microbes Infect 10: 251-259.
32. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, et al. (2003) Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198: 235-247.
33. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM, (2006) Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108: 2655-2661.
34. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, et al. (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
35. Liu G, Zhao Y, (2007) Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 122: 149-156.
36. Thornton AM, Shevach EM, (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296.
37. Pace L, Rizzo S, Palombi C, Brombacher F, Doria G, (2006) Cutting edge: IL-4-induced protection of CD4+CD25- Th cells from CD4+CD25+ regulatory T cell-mediated suppression. J Immunol 176: 3900-3904.
38. Wan S, Xia C, Morel L, (2007) IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 178: 271-279.
39. Walker LS, (2009) Regulatory T cells overturned: the effectors fight back. Immunology 126: 466-474.
40. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, et al. (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108: 253-261.
41. Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J, (2009) Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 174: 1575-1587.
42. Li J, Bracht M, Shang X, Radewonuk J, Emmell E, et al. (2006) Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses. Cell Immunol 241: 75-84.
43. Fontenot JD, Rudensky AY, (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6: 331-337.
44. Wan YY, Flavell RA, (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445: 766-770.
45. Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB, (2011) Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 41: 1334-1343.
46. Duthie MS, Windish HP, Fox CB, Reed SG, (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196.
47. Zhang X, Mosser DM, (2008) Macrophage activation by endogenous danger signals. J Pathol 214: 161-178.
48. Zhang WW, Matlashewski G, (2008) Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 76: 3777-3783.
49. Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, et al. (2004) Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22: 1782-1790.
50. Engel AL, Holt GE, Lu H, (2011) The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 4: 275-289.
51. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, et al. (2000) Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204: 64-74.
52. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 185: 1701-1710.
53. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, et al. (2010) Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 120: 607-616.
54. Farias LP, Cardoso FC, Miyasato PA, Montoya BO, Tararam CA, et al. (2010) Schistosoma mansoni Stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLoS Negl Trop Dis 4: e597.
55. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, et al. (2008) Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2: e308.
56. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776.
57. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, et al. (2008) Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 105: 16260-16265.
58. Conroy H, Marshall NA, Mills KH, (2008) TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27: 168-180.
59. Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, et al. (2011) An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 128: 897-907.
60. Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, et al. (2010) Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol 184: 6833-6842.
61. Kawai T, Akira S, (2007) TLR signaling. Semin Immunol 19: 24-32.
62. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, (2009) Regulatory T cells: how do they suppress immune responses? Int Immunol 21: 1105-1111.
63. Mosser DM, Zhang X, (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226: 205-218.
64. Lu LF, Rudensky A, (2009) Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev 23: 1270-1282.
65. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL, (2005) TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23: 5263-5270.
66. Mills KH, (2011) TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 11: 807-822.
67. Rajan N, Langtry JA, (2006) Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 31: 140-141.
68. Taylor JJ, Mohrs M, Pearce EJ, (2006) Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J Immunol 176: 5839-5847.